D uring the past decade heart transplantation has evolved from an experimental procedure performed in selected centers to the treatment of choice for patients with end-stage heart disease. The rapid increase in the number of heart transplants performed worldwide is attributable to numerous advances in surgery, tissue preservation, immunology, and infectious disease that have resulted in acceptable short-and long-term patient and graft survival. The improved outcome of heart transplantation is also due to the highly specialized care provided by physicians and surgeons who have made a strong commitment to heart transplantation and have acquired expertise in recipient selection, donor procurement, and medical follow-up before and after transplantation. Standardized criteria help physicians and surgeons identify patients who will likely benefit from heart transplantation. Unfortunately, the limited availability of donor hearts makes it impossible to offer transplantation to all potential candidates. The need for an equitable system of donor organ allocation was a factor in the organization of a national organ procurement and distribution network, the United Network for Organ Sharing (UNOS),* which distributes organs based on the severity of the recipient's illness, waiting time, donor and recipient's blood types, and body-size match.
In addition to maximizing access to donors and matching organs to specific recipients, other important aspects of a donor procurement program are knowledge of medical, ethical, and legal issues concerning brain death, skill in hemodynamic management of potential donors, and expertise in organ retrieval, preservation, and transport. *UNOS is responsible for maintaining the national computerized prioritization and allocation system and certifying transplant centers and local organ procurement organizations. "Cardiac Transplantation" was approved by the American Heart Association Steering Committee on February 19, 1992. Requests for reprints should be sent to the Office of Scientific Affairs, American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231-4596.
Heart transplantation is not a cure; thus, competent long-term treatment is essential for a successful outcome. Care of heart transplant recipients must focus on evaluation of heart allograft function, which is affected by denervation, donor-recipient size mismatch, rejection surveillance, and treatment of immunosuppression. Complications occurring after transplantation affect multiple organ systems and vary in type and frequency. Because most complications are a result of adverse effects of immunosuppression, successful outcome of heart transplantation requires a delicate balance between adequate immunosuppression and control of drug-related morbidity. This statement reviews recipient selection, donor procurement, and medical follow-up in heart transplantation.
Recipient Selection Selection of heart transplant recipients is based on a determination of which patients are likely to exhibit the most pronounced improvement in symptoms, functional capacity, and life expectancy after transplantation. The donor organ shortage precludes transplantation for all patients who may benefit from the surgery. Variation in recipient selection criteria among transplant centers is related to this dilemma. Therefore, an elaborate nationwide system, supervised by UNOS, has evolved. Equitable distribution of limited donor resources is based on length of recipient waiting time, severity of illness, blood type, and body size.
Deciding which patients should receive transplants requires knowledge of both potential benefits and expectations and the natural history of the illness for which transplantation is suggested. It should be understood that controlled trials have not compared the results of transplantation with those of medical treatment. As such, the precision of patient selection is limited.
Current Results in Transplantation and Medical Management
After successful cardiac transplantation, most recipients will be without functional limitation (i.e., will be in New York Heart Association [NYHA] Functional Class I) or have only mild limitations (NYHA Class II). The expectation for 1-year and 5-year survival after cardiac transplantation is 80-90% and 60-70%, respectively.' Therefore, any patient with a cardiac condition that has a lower survival rate could potentially benefit from transplantation. The magnitude of expected improvement in survival, functional capacity, and symptoms usually drives the decision-making process. In uncontrolled trials, patients in NYHA Class IV (symptoms at rest despite optimal medical therapy) with congestive heart failure and systolic dysfunction have annual survival rates of less than 50%.2-6 In a controlled trial involving NYHA Class IV patients (CONSENSUS), 1- year survival with optimal medical therapy (digoxin, diuretics, angiotensin-converting enzyme [ACE] inhibitors, and in many cases other vasodilators) was approximately 60%.2 Although the survival rate of patients who respond inadequately to this medical therapy has not been detailed, it is unlikely that this group will have a 1-year survival rate greater than 50%. Therefore, patients with severe impairment of cardiac function achieve maximal survival and symptomatic benefit from cardiac transplantation.
Results of uncontrolled studies suggest that 1-year survival in patients with NYHA Class III symptoms of congestive heart failure varies from 40% to 70%.3-7 The Studies of Left Ventricular Dysfunction (SOLVD) trial, in which investigators analyzed the effect of enalapril in a large cohort of Class II and Class III patients, suggests a better prognosis with medical treatment than previously noted in these patients. 8 Although improvement in survival and symptoms after transplantation is not expected to be as great as for Class IV patients, selected NYHA Class III patients may be acceptable candidates for the procedure and should be referred to a transplant center for further evaluation.
Selection of the Candidate for Transplantation
Because of the limited number of donors and the subjectivity of categorizing functional impairment, several investigators have attempted to identify other determinants of survival and provide guidelines for candidate selection.3-5,9-$ Patients with severely impaired left ventricular function (ejection fraction less than 20%) are at a higher risk than patients whose ejection fraction is 20% or greater.9'1 Patients with extremely poor left ventricular dysfunction, especially those requiring continuous intravenous inotropic support or mechanical assist devices, are probably at highest risk of mortality and therefore are most likely to benefit from transplantation. In ambulatory NYHA Class III patients, impairment of exercise tolerance (Vo2max <14 ilill/kgiiiiii') is a poor prognostic sign.'0 Indexes of risk should be obtained only after optimal medical therapy. The long-term survival of patients with symptomatically mild heart failure receiving optimal medical therapy (Veterans Administration Cooperative Vasodilator-Heart Failure Trial [V-HeFT] I and V-HeFT II and SOLVD) is comparable to the results of transplantation, particularly in the initial 3-5 years.8"123 Transplantation should generally not be considered for this group.
The most common illnesses leading to transplanta-disease with left ventricular dysfunction. The symptoms of patients with refractory angina pectoris and left ventricular dysfunction who cannot be treated successfully with revascularization or medical therapy improve or are eliminated after cardiac transplantation. Transplantation probably improves survival in this group of patients, who usually have extensive coronary artery disease.14 Patients with refractory life-threatening arrhythmias not amenable to medical therapy or the insertion of automatic implantable cardioverter devices may benefit from transplantation, as may those with valvular and congenital heart disease. Less common cardiac problems may also be improved by cardiac transplantation: for example, restrictive cardiomyopathy, sarcoidosis, amyloidosis, hypertrophic cardiomyopathy, myocarditis, and cardiac tumors.'5'6 Sarcoidosis is a relatively rare indication for transplantation and very few cases with longterm follow-up have been reported.'5 Although some benefit may be derived from cardiac transplantation if amyloidosis appears to be limited to the heart, progression of the systemic manifestations of this disease may limit the long-term efficacy of this procedure. 16 Transplantation in patients with active myocarditis has been successful. However, mortality and rejection rates may be higher in this group than in patients who do not have myocarditis. 17 Patients with tumors limited to the heart that cannot be resected by conventional surgical techniques may be successfully treated with transplantation.
Additional criteria have been established to identify the best recipient candidates. Those who do not have other conditions that might limit survival have the highest selection priority. A typical evaluation for cardiac transplant patients, which should be tailored to the specific clinical situation, is shown in Table 1 . Infection and malignancy, unless cured or controlled, are absolute contraindications to transplantation. The immunosuppression required to prevent allograft rejection will favor the progression of an active infection and may accelerate growth of certain malignancies. Pulmonary infarction is a relative contraindication to transplantation because secondary infection may occur postoperatively.'8 In many centers, patients with pulmonary infarction are treated with anticoagulant agents and monitored for at least 6-12 weeks or until radiographic improvement is documented before they are added to the list for transplantation. Alternatively, resection of the infarcted segments may be performed during the transplant surgery.
One of the most problematic relative contraindications to transplantation is age. The upper age limit for recipients in most transplant centers is between 55 and 65 years, although the benefits of transplantation in carefully selected older patients are comparable to those of a younger cohort.19,20 However, older patients may have other conditions that preclude transplantation. Preferential selection of older donors for older recipients has been the practice in some transplant centers.
Excessive elevation of pulmonary vascular resistance may cause right heart failure in the immediate postoperative period. 21 The absolute level of pulmonary vascular resistance that will produce right heart failure is unknown, but in most centers patients with pulmonary vascular resistance of more than 4-6 Wood units (4-6 tion are dilated cardiomyopathy and ischemic heart Although patients with severe fixed pulmonary hypertension are usually excluded from orthotopic heart transplantation, heterotopic ("piggyback") heart transplantation may be a viable alternative. "2 Increased pulmonary vascular resistance is particularly associated with decreased survival after cardiac transplantation in the pediatric population.29 Because of differences in lung size, body size, and absolute appears most appropriate to use pulmonary vascular resistance measurements indexed by body surface area, i.e., Wood units -m2 (u i m2), when assessing relative suitability for transplantation. The highest level of pulmonary arteriolar resistance for successful cardiac transplantation in children also has not been defined. There are data to support a continuous positive relation, as determined by multivariate analysis, between higher pretransplant pulmonary vascular resistance and mortality after transplantation in both adults and children. 30, 31 In patients with congenital heart disease, the risk of death is very significant when pulmonary vascular resistance is greater than 6-7 u -m2.30 Evidence of reversibility of the pulmonary vascular resistance with maximum treatment with inotropic and vasodilator drugs may indicate that cardiac transplantation in infants and children can be successful.
There are concerns about transplantation in patients with diabetes mellitus. Corticosteroids, frequently used in immunosuppression, increase the difficulty of controlling blood sugar. Patients whose diabetes has been controlled by diet or oral agents may require insulin postoperatively. Diabetics tend to have an increased frequency and severity of infections, and diabetics are at increased risk for vascular complications that decrease life expectancy. 32 Therefore, end-organ damage (neuropathy, nephropathy, or retinopathy) must be carefully excluded before the diabetic is accepted for transplantation. Intermediate-term (2-4-year) survival of some diabetics is comparable to that of nondiabetics.32-34 Therefore, insulin-dependent diabetes mellitus is no longer an absolute contraindication to transplantation.
Patients with irreversible moderate to severe liver or kidney disease generally have been excluded from con-sideration31 because of the expectation of limited survival due to involvement of those organs and the additional damage induced by immunosuppression. Moderate to severe chronic lung disease is a relative contraindication. A higher incidence of immediate postoperative respiratory problems, decreased survival due to the chronic lung disease itself, and the increased risk of lung infections due to immunosuppression have been noted. Generally an FVC (forced vital capacity) <50% predicted, an FEV1.0 (forced expiratory volume in 1 second) of less than 1 liter, or an FEV,.,/FVC ratio of less than 1 have been used as guidelines for predicting risk. Consequently, whether an active smoker should be considered a candidate for transplantation is highly questionable.
Peripheral or cerebral vascular diseases are also relative contraindications. Peripheral vascular disease may rarely preclude the use of intra-aortic balloon support and functional rehabilitation. A history of cerebrovascular disease, including previous stroke, also may limit long-term survival or rehabilitation. Asymptomatic carotid bruits are not absolute contraindications for transplantation.
Hyperlipidemia, cholelithiasis, and complications of diverticulosis are common after transplantation. 35, 36 Although their presence before transplantation is not a contraindication per se, preoperative identification aids in postoperative management. Previous cardiothoracic surgery is not a contraindication to cardiac transplantation. However, such patients may be at higher risk for bleeding and other complications in the immediate cardiac output in children of different ages and sizes, it postoperative period.37 Because cachexia may retard wound healing and increase the risk of postoperative infection, one goal of pretransplant care is to maintain adequate nutrition.38 Active peptic ulcer disease has been considered a possible contraindication because the use of corticosteroids may aggravate this condition; however, aggressive medical treatment usually eliminates it. Morbid obesity has also been considered a relative contraindication because it may increase postoperative morbidity, limit functional recovery, and make the identification of a suitably large donor almost impossible.
It is not unusual for the patient with chronic severe heart failure to feel depressed. Psychiatric consultation may be useful in determining whether the depression is related to the chronic illness or is endogenous and requires long-term treatment. The support of caring family members or other persons should be enlisted when possible. Commitment by the patient to a lifetime of medical treatment is essential for acceptance into a transplant program. Inability or unwillingness to comply with long-term medical care precludes further consideration for transplantation. This aspect of the selection process may be subjective and may be the focal point of disagreement among physicians. Although an adequate psychological instrument to test compliance has not been universally accepted, compliance with a rigorous treatment regimen for congestive heart failure may be objective evidence of the patient's suitability for transplantation. It is also important that the patient, or in the case of a child the parents or guardians, have the intellectual skills necessary to cope with multidrug therapy, frequent heart biopsies, and long-term medical care. It is crucial to ascertain that the candidate is not actively abusing drugs or alcohol. Postoperative recidivism in patients with a history of drug or alcohol abuse may be a problem.39'40 However, data on this possibility are limited and the decision must be made on an individual basis.
In assessing a patient's candidacy, financial resources must be evaluated. Most third-party carriers and government programs will pay for cardiac transplantation for eligible patients.41 Nevertheless, the cost of medical care and the patient's subsequent need for social support may still be formidable and review of finances should be part of the preoperative evaluation.
Infants and Children as Transplant Recipients
There are two major categories of potential transplant recipients: patients with complex forms of congenital heart defects, and patients with dilated cardiomyopathy. Hypoplastic left heart syndrome is the most common complex congenital heart defect for which cardiac transplantation is a potentially useful treatment in the neonate. In this condition the left ventricle and ascending aorta are too small to support normal systemic blood flow. The three major strategies for initial treatment of infants with hypoplastic left heart syndrome are supportive treatment with anticipation of death, the Norwood procedure, and cardiac transplantation. It is unclear which is best. Until sufficient midto long-term data are available, it is reasonable to offer cardiac transplantation to these patients as a treatment option.
Patients with other complex congenital cardiac or end-stage defects that are not amenable to conventional surgical repair or palliation may be acceptable candidates for cardiac transplantation. In general, the end stage of congenital heart defects results from severe ventricular failure. The guidelines for defining the end stage are similar to those listed below for dilated cardiomyopathy.
Cardiac transplantation is a reasonable treatment for infants, children, and adolescents with end-stage dilated cardiomyopathy. Unfortunately, the natural history of dilated cardiomyopathy is not well defined for this age group. This uncertainty is highlighted by a reported range of 6-year survival from 20% to 84%. [42] [43] [44] [45] It is difficult to know when cardiac disease has become end-stage and hence to know the optimum time for cardiac transplantation. Though no guidelines are absolute, the following can be helpful in identifying end-stage cardiac disease:
1. Progressive deterioration of ventricular function or functional status despite optimal medical care, including treatment with digitalis, diuretics, and angiotensin converting enzyme inhibitors 2. Growth failure secondary to severe congestive heart failure unresponsive to conventional medical treatment 3. Malignant arrhythmias, or survival of cardiac arrest, unresponsive to conventional medical treatment and not likely to be successfully treated with an automatic implantable cardioverter/defibrillator 4. Need for ongoing intravenous inotropic support 5. Unacceptably poor quality of life 6. Progressive pulmonary hypertension that would preclude transplantation at a later date Patients with congenital cardiac defects in which both ventricles are present are candidates for conventional reparative operations even when their levels of pulmonary vascular resistance are higher than that considered acceptable for low-risk cardiac transplantation. The most definitive conventional repair for patients with only one useful ventricle (i.e., tricuspid atresia and all variants of univentricular heart) is the modified Fontan operation. Pulmonary vascular resistance must be less than 4 u m2 for a successful modified Fontan operation. Whether cardiac transplantation should be offered to a patient with tricuspid atresia or univentricular heart whose pulmonary vascular resistance is greater than 4 u m2 but still within an acceptable range for cardiac transplantation is problematic, because the natural history of these patients and the ultimate morbidity and mortality for cardiac transplantation in children has not been fully defined.
Infants, children, and adolescents have additional unique psychosocial needs.., Adolescents in particular may rebel against the strict regimen required after cardiac transplantation. A parent or guardian may be the primary care giver for an infant or child, so the social, emotional, intellectual, and financial stability of the care provider must be assessed in the preoperative and postoperative periods. While a child should not be deprived of the potential benefit of cardiac transplantation because of a situation beyond his or her control, a precious donor organ should not be squandered if failure is inevitable because of an adverse psychosocial situation.
Strategies of Prioritization for Patient Selection and Donor Allocation
The availability of transplantable organs is limited. The subjective and interdisciplinary nature of the process of patient selection mandates a committee structure to facilitate fair and equitable consideration. The committees at most transplant centers include transplant surgeons, cardiologists, coordinators, social workers, and experts in relevant medical and ancillary disciplines.
In the United States, all patients awaiting heart transplantation are listed on the computerized system maintained by UNOS. Donor hearts are initially offered to compatible recipients on the waiting lists at local institutions. If a local recipient is not identified, the organ is then offered to candidates at more distant locations on the basis of severity of illness.
Many systems for fair, equitable prioritization of transplant candidates on the waiting list have been used. In the United States, UNOS mandates recipient prioritization based on time on the waiting list and two classes of clinical severity. UNOS status 1 (high priority) is given to potential recipients who are intensivecare bound and require intravenous inotropes or mechanical circulatory assistance. Status 2 designates all other recipients. This system requires continual reevaluation since patient status may change or the patient may be removed from the active waiting list if his or her condition improves. Although aspects of this system are now arbitrary, future donor organ allocation may be based on more objective determinants of successful outcome.
The Cardiac Organ Donor Ethical and Legal Concerns
Unlike bone, cornea, and skin, which may be harvested after circulatory arrest, solid vascularized organs such as the heart must be harvested while still functioning after brain death is declared. In the United States, criteria for brain death specify that death may only be declared when all brain functions cease according to reasonable medical standards ( Table 2 ).4748 Variations of the Uniform Anatomical Gift Act of 1968 establishing the framework for the consent for anatomical donations after death were passed in all states by 1972.47 Persons 18 years old or older may specify their preference about donating organs. In the absence of specific objection from the potential donor, the next of kin may consent to organ donation. The right to insist on organ donation from a consenting individual, despite objections from the next of kin, was proposed in 1987 and adopted in a few states.47 However, organ recovery teams avoid creating such conflicts because of possible negative influences on future organ donations.
Since 1986 hospitals receiving Medicare and Medicaid funds are required to establish protocols for documentation of donor status after all deaths. "Required request" legislation, which mandates that hospitals offer the option of organ donation to next of kin at the time of brain death, has been adopted in most states. 49 Presumed consent, whereby a brain-dead person is assumed to be a donor unless the person had specified otherwise, has been adopted in a few European countries and has substantially increased the number of hours; observation period for children aged 1-5 years is 12 hours. organs transplanted. In general, however, recovery teams in these countries do not harvest organs if there are strong objections from the next of kin.
In most cases, the declaration of brain death is made by the patient's attending physician, and options for disposition of the patient's remains, including organ donation, are presented to the family if they are available. A trained member of an organ procurement organization (OPO)* should explain the organ donation option to the family and obtain consent.50 If next of kin are not available, appropriate hospital or government personnel may authorize organ donation. Questions about a person's suitability as an organ donor or whether brain death criteria have been met should be referred to the regional OPO.
Donor Availability
Surveys in the United States have documented a gradual increase in both donor awareness and willingness to donate one's or a relative's organs.51 Despite this changing attitude, families frequently do not consider organ donation and occasionally refuse to donate the heart because of religious or cultural beliefs or inadequate knowledge of transplantation. It is estimated that only 10-20% of brain-dead patients with suitable hearts become actual donors. 50 The failure of medical professionals to pursue organ donation with a brain-dead patient's next of kin remains a major obstacle to transplantation.52 While the number of cadaveric donors has increased significantly since 1985, the number of cardiac transplants has peaked and leveled off at approximately 2,000 per year in the United States. ' The lack of cardiac *Local and regional organ procurement organizations are responsible for donor management and organ procurement and distribution. All OPOs in the United States are members of and agree to abide by the rules of UNOS. donors remains a major problem. On April 30, 1992, 2,486 people were on heart transplant waiting lists in the United States. 53 The donor shortage is grimly illustrated by the fact that at major transplant centers in the United States, 10-40% of patients die while awaiting transplantation.5154 Inadequate organ availability is certain to remain the major factor limiting the number of cardiac transplantation procedures performed. 55 The number of donors available per year in the United States has recently been estimated to be no more than 6,900- 10,700.56 Medical Treatment of Donors Potential cardiac donors are best treated in an intensive care unit, cared for by OPO-provided trained personnel using continuous hemodynamic monitoring, because multiple hemodynamic, hormonal, metabolic, pulmonary, and thermal changes accompany brain death. After brain death is declared, efforts should be shifted immediately from minimizing brain injury to maximizing perfusion and performance of transplantable organs.52,57- 61 The hemodynamic alterations that accompany brain death may include early transient severe hypertension and tachycardia due to excessive sympathetic tone. This hyperdynamic state is best treated by afterload reduction (using a vasodilator such as intravenous nitroprusside) and reduction of heart rate with a short-acting 13-blocker (i.e., esmolol). A loss of vasomotor tone and resultant hypertension usually follow, typically exacerbated by inadequate intravascular volume due to traumatic blood loss, diabetes insipidus (see below), and therapeutic interventions before brain death. Hypotension is initially treated with fluid replacement to maintain central venous pressure between 8 mm Hg and 12 mm Hg. If volume replacement fails to restore the systemic systolic blood pressure to 100 mm Hg, dopamine should be administered at less than 10 gg/kg per minute.60,61 Phenylephrine may also be used to maintain systemic vasomotor tone. Prolonged high doses of catecholamines should be avoided because early cardiac allograft dysfunction with decreased blood flow to the kidneys and liver may result. 61, 62 Central diabetes insipidus occurs in 38-87% of braindead patients and may induce massive diuresis.61 Adequate but not excessive crystalloid fluid replacement and correction of electrolyte abnormalities are needed to maintain blood pressure and avoid cardiac arrhythmias. Fluid replacement should be monitored carefully by determination of pulmonary capillary wedge pressure to ensure adequate hydration; overhydration may result in sudden cardiac chamber distention and pulmonary edema that may render the organ unsuitable for transplantation, and cardiac chamber overdistention may contribute to early allograft dysfunction after transplantation. Low-dose continuous vasopressin infusion will reduce the urine output to 100-300 ml/hr, but bolus or high-dose continuous infusion should be avoided because of the severe vasoconstriction that may result, causing increased afterload and decreased cardiac output. Vasoconstriction also directly affects the renal and splanchnic vasculature, potentially damaging transplantable organs.
Clinical and experimental evidence suggest that ab-may contribute to donor heart dysfunction.52 Controlled studies of the use of triiodothyronine in the cardiac organ donor and recipient are in progress. Other metabolic abnormalities associated with brain death include hypernatremia, hypokalemia, and hypomagnesemia, electrolyte abnormalities related to diabetes insipidus. Mechanical hyperventilation used to lessen cerebral edema often leads to severe hypophosphatemia.63 Volume and crystalloid replacement, adjusted for these abnormalities, should be given with frequent serum electrolyte measurements. Brain death is accompanied by thermoregulatory abnormalities. Initial hyperthermia followed by hypothermia is often observed. Fever may be mistaken for a sign of systemic infection. Hypothermia may be aggravated by unwarmed fluid replacement and may lead to cardiac arrhythmias and decreased cardiac output. In general, a body temperature below 35°C should be corrected by heating blankets.
Pulmonary dysfunction after brain death may be aggravated by underlying lung trauma, infection, aspiration pneumonia, atelectasis, and neurogenic pulmonary edema. These problems should be prevented or treated and the lungs should be considered for donation.
Medical Evaluation of Donor
An evaluation of the cardiac donor must be performed (Table 3 ). Echocardiography may be used to evaluate left and right ventricular function, and coronary angiography may be required to rule out obstructive disease suspected because of the donor's age or atherosclerosis risk factor profile. Invasive hemodynamic monitoring allows serial assessment of cardiac output and volume status. Positive serologies for hepatitis B surface antigen and human immunodeficiency virus remain absolute contraindications for donation to serologically negative recipients. Hepatitis C titers should not necessarily exclude donation. Other viral serologies and blood typing are performed to help match the donor heart with a compatible recipient.5052,5461 Although not currently feasible, HLA typing may be useful in assessing compatibility of the donor and recipient.
Donor Selection Criteria and Donor-Recipient Matching
There are several suggested cardiac donor criteria for cardiac transplantation (Table 4 ). Donor organ allocation is also based on ABO blood group compatibility, donor-recipient weight match, severity of recipient illness, and waiting time. 54 Preformed anti-human lymphocyte antigen IgG antibodies with donor specificity may cause potentially fatal hyperacute rejection. Before transplantation the potential recipient is screened for circulating antibodies to various human lymphocyte antigens with a panel of blood cells representing diverse human lymphocyte antigen specifications (percent, or panel, reactive antibody [PRA] ). Exposure to foreign HLA antigens, due to previous blood transfusions or pregnancy, results in higher probability of a reactive PRA. If the PRA is greater than 5-15%, most cardiac transplant centers require a negative prospective crossmatch between donor and recipient sera.5463, The requirement for a normalities in thyroid function occurring at brain death prospective crossmatch, which delays organ harvesting, may markedly prolong a recipient's waiting time. 54 Data for donor-recipient weight matching are limited. It has been suggested that oversizing of donor hearts, compared with recipient's hearts, may actually have a negative effect on survival, and that a donor-torecipient weight ratio as low as 0.5 does not negatively affect survival. 65 Additional issues in donor-recipient matching include recipient heart size, and therefore the size of the pericardial space; conditions indicating scar tissue and adhesions, such as prior sternotomy or radiation therapy to the thorax; and the prolonged use of intrathoracic ventricular support devices.
To increase the cardiac donor pool, the criteria for acceptability has been expanded at many centers. The use of organs from older donors has specifically been advocated. [66] [67] [68] [69] [70] In one institution, short-term survival did not seem to be affected by transplantation of older donors' hearts with simple analysis of variance.70 However, a multicenter multivariate analysis of data from 911 patients identified older donor age as a risk factor for death after cardiac transplantation when donor age was analyzed as a continuous variable.31 Extending allograft ischemic time (time from procurement to reperfusion of the heart in the recipient) to more than 4 hours has been attempted under special circumstances at many cardiac transplant centers.66'69 However, early allograft function and survival is significantly poorer when ischemic times are more than 4-5 hours.31
Cardiac Size Matching in Pediatric Cardiac Transplantation
The selection of a donor heart of appropriate size is particularly important in pediatric patients, who range in size from that of a newborn to that of an adult-sized adolescent. Although there is not uniform agreement about size matching, the following guidelines may be helpful.
The limiting factor for use of an oversized donor heart is the heart size the recipient's chest will accommodate. There are few data to indicate that an oversized donor heart will adversely affect outcome in the pediatric population. For infant recipients, the body weight of the donor should be no more than three times the body weight of the recipient. For recipients more than 18 months old, the body weight of the donor should be no more than 25-50% of the recipient's weight.
In general, a heart from a donor who weighs less than the recipient should not be used. For children and adolescents the donor's body weight should be no less than 75% of the recipient's weight. The transplanted heart will grow with the recipient.71 Very low probability of coronary artery disease (coronary angiograms may be required to ascertain its absence) Normal or acceptable ventricular function after intravascular volume normalization; dopamine less than 10 mcg/kg per minute Blood type (ABO) compatibility with recipient Donor body weight usually between 80% and 120% of recipient's body weight If required (see text), negative prospective cytotoxic T cell crossmatch. A retrospective crossmatch is performed in most centers Anticipated allograft ischemic time less than 4-5 hours Organ Retrieval and Transport Several organs are now procured from most donors, requiring cooperation and timing among the heart, kidney, liver, pancreas, and lung procurement teams. Coordination of these activities is the responsibility of the OPO. The final acceptance of a donor heart is made after physical inspection of the heart by the procuring surgeon. Precise heart dissection, rapid cardioplegia administration, cardiectomy, and placement of the heart in a cold transport container requires an experienced and knowledgeable heart procurement team. In certain circumstances multiorgan procurement can be safely performed after the donor has been placed on cardiopulmonary bypass. Rapid ground and air transport must be prearranged by the OPO. Occasionally, the procurement is performed by a team from one medical center and the heart is then transported by OPO coordinators to another center for implantation. Unlike kidneys, hearts cannot be kept viable on a perfusion device that would allow delayed implantation. Transplantation is timed to synchronize cardiectomy with arrival of the donor organ.5052,72
Postoperative and Long-term Medical Follow-up Expert long-term management is essential for a successful outcome. Patients must accept a lifelong commitment to medical care, because complications may occur at any time. In addition, patients must assume an active role in their health care by learning to monitor vital signs, recognize and promptly report symptoms of rejection and infection, and make appropriate changes in medications upon instructions from the physician. Cardiologists dedicated to transplantation must be knowledgeable in immunology and infectious diseases, areas that traditionally are not included in subspecialty training in cardiovascular disease. Because complications after heart transplantation involve multiple-organ systems, medical care requires a multidisciplinary approach with the input of specialists in the areas of infectious disease, nephrology, gastroenterology, neurology, endocrinology, pulmonology, gynecology, oncology, pathology, social work, and nursing.
After heart transplantation cardiovascular physiology is affected by denervation, donor-recipient size mismatch, rejection, and immunosuppression. Allograft rejection remains the major life-threatening complication, yet immunosuppression is the major source of morbidity. Therefore, the follow-up of heart transplant recipients must be focused on evaluation of heart allograft function, rejection surveillance, management of immunosuppression, and diagnosis and treatment of immunosuppression-induced adverse effects.
Evaluation and Management of Heart Allograft Function
Effective management requires a working knowledge of the unique physiological responses to transplantation, the effects of cardiovascular drugs on the denervated heart, and the effects of rejection on allograft function. Because the heart is denervated for at least the first year after transplantation, resting heart rate is higher than that of an innervated heart and increases only gradually with exercise.65 7374 Partial or complete denervation prevents perception of cardiac ischemic Table 5 ). Drugs with a direct effect on the atrioventricular node, such as verapamil and ,B-blockers, may be used to treat supraventricular arrhythmias; adenosine, though effective, should be used at a much lower dose because the denervated human heart is supersensitive to the effects of adenosine.75 Drugs that act indirectly via autonomic stimulation are not generally effective in these patients. Restrictive hemodynamics detected in some patients are attributed to rejection, cyclosporine, and donorrecipient weight mismatch.76 Pericardial effusion is common early after transplant but a late effusion suggests rejection. Heart Allograft Rejection Acute rejection. The clinical manifestations of acute rejection are highly variable. Rejection is usually detected by routine outpatient surveillance endomyocardial biopsy before the appearance of any symptoms. Occasionally, however, acute rejection produces malaise, reduced exercise tolerance, low-grade fever, or reduction in blood pressure. The physical examination may reveal increased jugular venous pressure and the appearance of a third heart sound. Even with close follow-up acute rejection may, rarely, appear to be severe cardiac dysfunction or shock. Supraventricular arrhythmias may also be a manifestation of rejection. Acute rejection is more common in occasionally noncompliant patients who consider themselves cured and discontinue or reduce immunosuppressive therapy. Although noninvasive techniques for diagnosis of rejection have been proposed, endomyocardial biopsy remains the procedure of choice in patients older than 6 months or heavier than 5 kg. Typically, endomyocardial biopsy is performed weekly for the first 4-8 weeks after transplantation. Endomyocardial biopsy frequency is reduced progressively over subsequent months to 3-4 times per year. If acute rejection is detected, endomyocardial biopsy is usually repeated within 2 weeks.
The indication and timing of endomyocardial biopsy in infants differs from that of adults, children, or adolescents. For children younger than 6 months or smaller than 5 kg, myocardial biopsies are performed only selectively because of the morbidity associated with the procedure. Use of this technique is based on the need to confirm noninvasive indications of possible cardiac rejection. 29 The diagnosis of rejection is made by histologic changes observed on endomyocardial biopsy samples. The optimal frequency of biopsy sampling is unknown. A standardized endomyocardial biopsy rejection grading system has recently been established by the International Society for Heart and Lung Transplantation ( Table 6 ).77 Mild rejection characterized by a mononuclear inflammatory infiltrate without myocyte necrosis often reverses spontaneously in patients given therapeutic doses of corticosteroids, cyclosporine, and azathioprine. In some centers mild rejection either remains untreated, especially if the transplantation was long ago and the patient is clinically stable, or is treated only if persistent or progressive. In other transplant centers mild rejection is treated with an increased dosage of cyclosporine or oral prednisone. If myocyte necrosis (indicating moderate or severe rejection) accompanies mononuclear cell infiltration, immunosuppression is generally intensified by administration of high-dose oral or intravenous corticosteroids and/or antilymphocyte antibodies.78,79 Because rejection indicates the failure of maintenance immunosuppression to prevent activation of the immune effector cells that produce allograft injury, clinicians should always attempt to identify possible precipitating factors. These may include noncompliance, a fall in cyclosporine levels due to excessive dose reduction or drug interaction, discontinuation of azathioprine because of leukopenia, or reduction in immunosuppression necessitated by infection. In many or most instances, however, no precipitating factor is readily apparent. Cardiac allograft vasculopathy. Cardiac allograft vasculopathy, a unique form of coronary artery disease, is the major factor limiting long-term survival of heart transplant recipients.3' The prevalence of this complication is approximately 10-15% by 1 year, 15-25% by 2 years, and 35-50% by 5 years after transplantation. [80] [81] [82] Although the immunopathogenesis of cardiac allograft vasculopathy remains largely unknown, evidence suggests that the lesion results from an immune-mediated injury.80,83-85 Conventional risk factors for atherosclerosis that are also risk factors for cardiac allograft vasculopathy include older (donor) age and hyperlipidemia.86 Differences in immunosuppressive protocols, such as the use or avoidance of immunosuppressive prophylaxis, anti-T cell antibody type (monoclonal or polyclonal), long-term use of or withdrawal from corticosteroids, have not been shown to affect the incidence and severity of cardiac allograft vasculopathy. 82 There are many important differences between cardiac allograft vasculopathy and coronary atherosclerosis in the nontransplanted heart. Cardiac allograft vasculopathy is usually diffuse, involving epicardial, myocar-dial, and microscopic vessels. Its most striking histological features are intimal proliferation, mononuclear cell infiltration, and presence of lipid-laden macrophages throughout the vessel wall.86 These abnormalities may be detected, though rarely, on endomyocardial biopsy samples. 87 Cardiac allograft vasculopathy is usually not suspected clinically since patients may not experience angina because of heart denervation. Its first manifestation may be congestive heart failure or sudden death due to ischemia or infarction. Noninvasive screening tests such as exercise electrocardiography, thallium scintigraphy, exercise radionuclide ventriculography, and ambulatory electrocardiography are sometimes helpful in making a diagnosis, but generally are not sensitive or specific enough to be considered reliable screening tests. 88 Coronary angiography is the only technique for establishing the diagnosis of cardiac allograft vasculopathy and should be performed when cardiac symptoms occur in the absence of histopathological evidence of rejection. Use of coronary angiography may lead to underestimation of the severity of cardiac allograft vasculopathy because of diffuse and concentric luminal narrowing89; severe cardiac allograft vasculopathy has been found at autopsy in patients whose coronary angiography, performed shortly before death,89 was normal. Intracoronary ultrasound may improve the sensitivity of diagnostic techniques, but the utility and safety of this technique remains to be defined. Baseline and follow-up angiography is used in most centers to guide therapy.
The efficacy of measures to prevent cardiac allograft vasculopathy, including anticoagulation therapy, administration of antiplatelet agents, weight reduction, and low-fat, low-cholesterol diets is unestablished.90 A preliminary analysis of an ongoing trial suggests the calcium-channel blocker diltiazem may be of prophylactic value.91 For cases of established cardiac allograft vasculopathy retransplantation is common but is associated with a significantly lower 1-year survival than the first heart transplant (55% comnpared with >80%).92 Coronary angioplasty may be used to treat patients if discrete lesions of the proximal coronary arteries are present. 89, 93 Coronary artery bypass grafting has been used but is generally avoided due to the diffuse nature (often undetected by coronary angiograms) of cardiac allograft vasculopathy.94 Medical therapy for established cardiac allograft vasculopathy is empiric and should be directed at preventing ischemia. The lack of effective prophylaxis or therapy is the rationale for an ongoing broad-based research effort.
Immunosuppression
Insufficient immunosuppression may result in rejection that threatens allograft and patient survival, and excessive immunosuppression increases the risk of infection and malignancy. The variability of patients' responses, due to individual characteristics, multiple environmental influences, drug-induced complications, drug interactions, and patient compliance, calls for constant monitoring and adjustments of the immunosuppressive regimen. In addition, conditions such as acute infection, malnutrition, and surgical complications may require a reduction in the immunosuppression regimen. Not all adverse effects of immunosuppression should prompt dosage reduction, because maintenance of adequate immunosuppression is crucial to long-term allograft and patient survival. Immunological maturation and senescence can positively or negatively affect the amount of immunosuppression required. Females reject transplanted organs more frequently than do males and thus require more intensive immunosuppression. 95 Immunosuppression in growing children should be designed to minimize adverse affects on growth.
Immunosuppressive Drugs
Azathioprine. Azathioprine, a purine antimetabolite converted in the liver to 6-mercaptopurine, is a potent but nonspecific immunosuppressive agent that inhibits lymphocyte proliferation. 96 The dose of azathioprine must be adjusted according to changes in patient weight, and decreased if severe leukopenia, anemia, or thrombocytopenia occur.9798 Mild leukopenia (<4,000 white blood cells/mm3) and anemia do not warrant changes in azathioprine dose. High-dose trimethoprim-sulfamethoxazole increases the risk of thrombocytopenia in azathioprine-treated patients. Because the enzyme xanthine oxidase controls 6-mercaptopurine levels, to avoid excessive bone marrow toxicity, azathioprine dosage must be reduced by as much as 75% when allopurinol is used. 98 Corticosteroids. Corticosteroids inhibit gene transcription for cytokines, which affect nearly all immune responses. 99 While the basic strategy is the same among heart transplant centers, corticosteroid dose protocols vary significantly. Most centers use high-dose methylprednisolone intravenously in the immediate perioperative period. Subsequently, prednisone administration is initiated, and its dose is tapered. Withdrawal of corticosteroids has successfully reduced long-term adverse effects in some heart transplant programs.'00 It must be remembered that diabetics, children, and older patients are more susceptible to the adverse effects of corticosteroids and corticosteroid doses in these patients should be reduced more rapidly.
Cyclosporine. Cyclosporine is a cyclic endecapeptide that inhibits immune responses by inhibiting T cell lymphokine production.'01 Patients may receive cyclosporine perioperatively, and doses are adjusted frequently to maintain target plasma or whole blood levels and avoid toxicity. Because of variability in dose requirement, precise manipulation of cyclosporine dosage is required for maintenance of a target blood level.101"102
The absorption of this highly lipophilic drug is affected into the proximal jejunum.101 Thus, abnormalities in gastrointestinal function caused by previous surgery, diabetic enteropathy, ileus, malabsorption, or viral gastroenteritis may dramatically decrease drug absorption. Plasma or serum levels of cyclosporine must be measured frequently and dosage altered appropriately. Drug interactions with cyclosporine are common and some drugs should be avoided if possible (Table 7) . Cyclosporine levels must be measured frequently when new drugs are added to the treatment regimen. The inhibition of cyclosporine metabolism by drugs such as ketoconazole and diltiazem reduce cyclosporine dose requirement and cost. If cyclosporine levels change abruptly, the possible causes that must be considered and carefully excluded include drug interactions, laboratory error, altered absorption, noncompliance, or an intercurrent illness such as hepatitis or gastroenteritis. If severe diarrhea or vomiting occurs and lasts for more than 36-48 hours, an empiric dose increase or the use of intravenous cyclosporine is warranted. The intravenous dose, administered as a continuous infusion, is usually one fourth to one third the oral dose.10y
The determination of cyclosporine levels is also difficult because of the use of several different assays, which produce widely differing results.105-'08 Therefore, physicians caring for patients taking cyclosporine must know which assay was used to correctly interpret the meaning of the assay results and make appropriate dose changes. Cyclosporine can have adverse effects ( Table 8 ).
The effect of immunoprophylaxis, by routine administration of antilymphocyte preparations or monoclonal antibodies early after transplant, on the required dose of maintenance immunosuppressants, and thus on morbidity due to them, is not yet resolved. Clinical trials of immunosuppression with FK506, mycophenolate mofetil (RS-61443), and photopheresis have been started. These agents may be incorporated into maintenance immunosuppression protocols within this decade and consequently, the morbidity of conventional immunosuppression will be reduced or eliminated by substitution of the causative agent by a less toxic immunosuppressant.
Complications Related to Immunosuppression
Infection. The Registry of the International Society of Heart Transplantation reports that infection is the most common cause of postoperative death.' A multicenter study of 24 very active transplant centers recently found that infection was the major cause of perioperative and postoperative mortality after cardiac transplantation. In this study of 814 patients, during a mean follow-up of 8.1 months, 409 serious infections occurred, of which 46% were bacterial, 40% were viral, 7% were fungal, and 5% were protozoal.109 Perioperative bacterial infections such as mediastinitis, pneumonia, urinary tract infections, and intravenous catheter-induced sepsis are treated conventionally.1"0"'11 Opportunistic infections transmitted by the donor organ and blood products may result from reactivation of latent viruses or may be caused by air-, water-, or feces-borne organisms.1"2 HERPES VIRUSES. Cytomegalovirus, a member of the herpesvirus group, is the infection most commonly transmitted by the donor heart. Fifty percent to 80% of adults have detectable IgG antibodies to cytomegalovirus. Transmission of cytomegalovirus from a cytomegaby the fat content of meals and the release of bile acids lovirus-seropositive donor heart to a cytomegalovirus- used in centers where cytomegalovirus morbidity is prevalent. Reactivation of herpes simplex or zoster, a bothersome but usually not life-threatening problem, may be prevented with oral low-dose acyclovir and treated with oral or intravenous acyclovir.124
ToxoPL4ASMA GONDII. The incubation period, latency, and pathogenesis of Toxoplasma gondii infections are similar to those of cytomegalovirus.125 Common manifestations of the primary infection, usually more severe than illness due to reactivation, include encephalitis, myocarditis, and pneumonitis. When Toxoplasma gondii infection is suspected, endomyocardial biopsy findings of inflammation and necrosis should prompt careful search for cysts.126 Central nervous system involvement is frequent, so a lumbar puncture should be included in the diagnostic evaluation.
Infection with Toxoplasmosis gondii is treated and prevented by pyrimethamine and sulfadiazine, or clindamycin in patients allergic to sulfonamides.127128 Prophylaxis is recommended when a seropositive donor organ is transplanted into a seronegative recipient. PNEUMOCYSTIS CARINI. Pneumocystis carinii a protozoal infection, should be suspected in heart transplant recipients who have fever, dyspnea, profound hypoxemia, and radiographic evidence of diffuse pulmonary infiltrates.'29"130 Early diagnosis of Pneumocystis carinii pneumonia with methenarnine silver stain of bronchial secretions or lavage specimens and aggressive treatment is lifesaving. Ventilatory assistance and hyperalimentation should be initiated early in patients with severe disease. Specific treatment is high-dose trimethoprim and sulfamethoxazole for at least 4 weeks. Because cytomegalovirus pneumonia often occurs concomitantly with Pneumocystis carinii, cytomegalovirus infection should be suspected in patients with Pneumocystis carinii when hypoxemia persists despite institution of the appropriate antimicrobial therapy.'3' Infection with Pneumocystis carinii can be prevented by administering inhaled pentamidine or oral low-dose trimethoprim and sulfamethoxazole if the frequency of infection in a transplant center is high.132 OTHER INFECTIONS. Occasionally pneumonia in heart transplant recipients is due to Legionella pneumophila. 33 The diagnosis is easily overlooked unless direct fluorescent antibody stain of appropriate sampling is performed. High-dose intravenous erythromycin is the treatment of choice. Because this antibiotic sharply increases plasma cyclosporine levels, the dose of cyclosporine should be decreased appropriately and its plasma levels determined regularly to prevent drug toxicity. Fever and meningitis in heart transplant recipients may be caused by Listeria monocytogenes, which can usually be cured by a 6-week course of high-dose intravenous ampicillin.134 Mucocutaneous candidiasis is not uncommon in heart transplant recipients and can be prevented and treated with clotrimazole or nystatin.135 Solitary or multiple pulmonary nodules in immunosuppressed patients can be due to Nocardia asteroides, which can also cause retinitis, meningitis, and epididymitis. A prolonged course of sulfa drugs is required for treatment. Minocycline can be added when Nocardia asteroides is resistant to sulfisoxazole.136 Debilitated heart transplant recipients receiving intensified immunosuppression for refractory or recurrent rejection or who have other opportunistic infections while taking multiple antibiotics are at higher risk of contracting aspergillosis. Infection may also occur in immunosuppressed patients exposed to high-density air-borne fungus and particularly to dust generated by construction. A solitary pulmonary lesion is treatable with antifungal drugs or surgical excision. Disseminated aspergillosis is usually fatal. The success of treatment with amphotericin B is limited by renal and bone marrow toxicity; however, the toxicity of a liposome-encapsulated formulation of amphotericin B is significantly lower than that of other formulations.137"138 Itraconazole shows promise as an orally administered treatment for this infection.
Infection will be a frequent postoperative complication after heart transplantation until more specific immunosuppressive regimens are developed. Therefore, fever is one of the most common clinical problems facing transplant physicians. Because the febrile response is blunted by corticosteroids, even mild elevations of body temperature should not be disregarded and the etiology of the fever should be aggressively investigated. A thorough history and physical examination may identify the location of the infection. Whether or not these are present, a complete blood count with differential, chest x-ray, and bacterial, viral, and fungal cultures of blood, urine, and sputum should be performed in dyspneic patients. Unexplained hypoxemia (greater than 10% reduction in baseline arterial P02) or a new pulmonary infiltrate must be investigated with bronchoscopy, bronchoalveolar lavage, and transbronchial biopsy. It is rarely necessary to perform open lung biopsy to make a definitive diagnosis. The evaluation of patients with fever and gastrointestinal symptoms should include endoscopy, with brushing and biopsy for culture as well as staining to identify CMV inclusions bodies. Computerized axial tomography and lumbar puncture should be performed immediately in patients with neurological abnormalities. Because infections in immunosuppressed patients may have an insidious onset and become rapidly fatal, the input of pulmonologists, infectious disease specialists, gastroenterologists, and neurologists is imperative.
Infective endocarditis is a rarely reported complication after cardiac transplantation. Although its efficacy is not supported by trials, endocarditis prophylaxis is tory, gastrointestinal, and genitourinary tract procedures that are likely to cause bacteremia.
Immunizations. After cardiac transplantation, the immunosuppressed recipient should not be given live viral vaccines, which include MMR (mumps, measles, rubella) and Sabin oral polio vaccines. Diphtheria, pertussis, tetanus, and Salk vaccines do not contain live viruses and can be administered safely. In addition, pneumococcus and Haemophilus infiuenzae vaccines can be administered.29 '139 The immunization status of infants and children who are potential cardiac transplant recipients should be as up to date as possible. However, two factors may limit the physician's ability to update the patient's immunization status. Because it cannot be known exactly when a patient on an active transplant waiting list will undergo transplantation, one cannot administer live vaccine to patients on an active transplant list, because shedding of live virus can occur for many months after administration of the vaccine, the period of shedding could potentially extend into the period of immunosuppression. 29"39 Immunologically normal siblings and other household contacts of immunosuppressed recipients should not receive oral poliovirus immunization because the virus is transmissible. However, these siblings and household contacts can and should receive measles, mumps, and rubella immunization because transmission of these viruses does not occur.29'39 Also, these siblings and other household contacts should receive Salk polio immunization.139 Immunization of the recipient with influenza vaccine is controversial.
Hypertension. Most heart transplant recipients develop cyclosporine-induced hypertension. Their highest daily blood pressures will be in the morning because of increased salt retention at night. Morning blood pressure values should therefore be used to guide antihypertensive therapy. Cyclosporine-induced hypertension is rarely controlled by diuretics alone. Nifedipine and perhaps the other dihydropyridine calciumchannel blockers are effective and appear to be better tolerated in the sustained-released preparation, which is less likely to cause wide fluctuations of blood pressure. Another calcium antagonist, diltiazem, may also be effective, but it significantly decreases cyclosporine requirements by increasing plasma levels.145146 Other calcium antagonists (nicardipine, verapamil), direct vasodilators (hydralazine) and pl-blockers have been used to treat posttransplant hypertension with variable success. ,l-blockers should be used with caution because the denervated transplanted heart relies on catecholamines to augment systolic performance, and the negative inotropic effect of these agents may be enhanced in the allograft. Angiotensin-converting enzyme inhibitors may also reduce blood pressure in cyclosporine-treated patients. 147 The use of multiple antihypertensive agents frequently becomes necessary in most transplant recipients for adequate blood pressure control.
Renal Effects. When cyclosporine is administered perioperatively, renal dysfunction may occur as a result of cyclosporine-induced renal vasoconstriction superimposed on the effects of chronic renal hypoperfusion (due to congestive heart failure), third space loss of albumin and fluids (due to the use of extracorporeal circulation), and maldistribution of blood flow (due to frequently recommended before dental, upper respiraanesthetic and inotropic drugs). 146 The incidence of acute cyclosporine nephrotoxicity may be decreased by delaying initiation of cyclosporine until 5-7 days after operation while antilymphocyte preparations are routinely administered or by reducing cyclosporine loading doses. '48 Chronic cyclosporine nephrotoxicity is characterized by irreversible interstitial fibrosis.149 Creatinine clearance will be reduced and serum creatinine elevated by 1 year after transplantation in virtually all cyclosporinetreated patients. 150 Cyclosporine levels, endomyocardial biopsy findings, and intensity of adverse effects are considerations in selecting a cyclosporine dose that minimizes renal dysfunction but prevents rejection. Cyclosporine nephrotoxicity does not generally progress after 1 year, partly because cyclosporine serum levels required to prevent rejection may be reduced.
To minimize chronic nephrotoxicity, cyclosporine doses should be adjusted when drugs that raise cyclosporine levels are administered. In addition, fluid loss due to fever, vomiting, or excessive diuresis should be corrected promptly. Decreases in intravascular volume are poorly tolerated by the kidneys of cyclosporinetreated patients and may result in a sharp increase in serum creatinine.
Gastrointestinal Complications. Dysphagia in heart transplant recipients suggests fungal or viral esophagitis that is usually due to Candida albicans or Herpes simplex. Endoscopy and biopsy are required for diagnosis. Herpes esophagitis is treated with intravenous acyclovir; candida esophagitis is treated with oral nystatin, clotrimazole, or, in severe cases, intravenous amphotericin B.
Epigastric pain, abdominal bloating, and nausea may result from gastritis or ulceration due to either peptic ulcer disease induced by stress, corticosteroids and antiplatelet agents, or cytomegalovirus infection. As in the case of dysphagia, endoscopy and biopsy are required for diagnosis. Therapy should include H2-receptor blockers, antacids, and sucralfate. If cytomegalovirus inclusions are demonstrated, a 14-day course of ganciclovir should be instituted. Infection with cytomegalovirus may result in ulcerations of the lower gastrointestinal tract that produce abdominal pain and rectal bleeding. Another lower gastrointestinal complication is perforation of preexisting diverticula.'5' Because symptoms and signs may be masked by corticosteroid treatment, this condition may remain unrecognized and become lifethreatening.
Hepatocellular enzyme abnormalities after heart transplantation may result from viral hepatitis due to cytomegalovirus or hepatitis B or from the effects of drugs such as cyclosporine and azathioprine. Cyclosporine hepatotoxicity is dose-dependent. The activation of azathioprine, which is converted to 6-mercaptopurine in the liver, is delayed in patients with hepatitis. Prednisone is converted to its active compound, prednisolone, in the liver, and substitution should be considered if liver function is severely impaired.
Corticosteroid therapy may cause or aggravate cholelithiasis. Pancreatitis, which occurs in approximately 10% of heart transplant recipients, may be related to hypoperfusion, inotropic agents, cytomegalovirus infection, drugs (e.g., corticosteroid, azathioprine, cyclosporine), or cholelithiasis. 152 Endocrine and Metabolic Abnormalities. Metabolic primarily to corticosteroids and cyclosporine. Corticosteroid therapy may worsen glucose intolerance or induce diabetes mellitus. In insulin-dependent diabetics, higher insulin doses may be needed, and in diabetics treated with oral agents, insulin may be needed after transplantation. Corticosteroids accelerate osteoporosis by increasing resorption and decreasing formation of bone. Older patients and postmenopausal women are at highest risk. Dietary calcium and vitamin D supplementation and low-dose estrogen therapy are widely used for prevention, but their efficacy has not been established. Corticosteroid therapy may cause aseptic necrosis of hips, knees, or shoulders. Accurate diagnosis can be made by magnetic resonance imaging. Symptoms of osteonecrosis may improve with dose reduction or discontinuation of corticosteroid, but joint replacement is frequently necessary. 153 The growth of most pediatric transplant recipients is retarded by corticosteroids. 154 Sexual or menstrual dysfunction is common early after heart transplantation and often recurs when corticosteroid doses are increased. However, with resolution of the changes of congestive heart failure and with clinical stability, the loss of libido and sexual dysfunction so common in patients in end-stage heart failure usually resolves and fertility returns in most patients. There is no reported evidence of teratogenicity in children of male patients taking immunosuppressants.
An important minority of heart transplant recipients are young women, and it is important to address the advisability or safety of childbearing by such women. There is little data on childbearing by heart transplant recipients (five reported cases as of 1991); but, based on data from renal allograft recipients on similar immunosuppressive regimens, pregnancy in an allograft recipient is associated with a high incidence of premature births and of babies small for gestational age. However, there are no data suggesting teratogenicity or any long-term adverse sequalae in children of allograft recipient mothers and no evidence of adverse affect of pregnancy on the health of the mother.155 Thus, advice to the individual patient must be based on review of such data as well as on discussion of the personal beliefs of the patient who understands that she may not survive to raise the child to adulthood. Methotrexate and cyclophosphamide may cause congenital anomalies, while corticosteroids and azathioprine are said to be safe in this regard. An increased incidence of spontaneous abortions, fetal anencephaly, and absence of the corpus callosum have been reported with cyclosporine.
For the above reasons transplant recipients should be discouraged from becoming pregnant and oral contraception or tubal ligation should be seriously considered. The effects of immunosuppression drugs on male fertility and genetic damage is unknown.
Both corticosteroids and cyclosporine cause hypercholesterolemia, the latter by impairing hepatic clearance of low density lipoproteins.156"57 Serum cholesterol levels are significantly lower in patients no longer taking corticosteroids.'58159 Treatment includes dietary restriction of fat and cholesterol, weight loss, and lipidlowering agents. Lovastatin and other HMG CoA (3hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors are associated with an increased risk of rhabdomyolysis and renal injury when used by cycloabnormalities after heart transplantation are related sporine-treated heart transplant recipients.160 Concomitant gemfibrozil administration increases the likelihood of this adverse reaction. Lovastatin should be started at low doses (10-20 mg/day) and discontinued immediately if liver dysfunction or elevation of skeletal muscle enzymes are detected.161 Bile acid-binding agents may be effective but they are poorly tolerated and impair cyclosporine absorption.
Neurological Complications. Seizures may occur after cardiac transplantation. 162 The multifactorial etiology of these seizures includes embolic, metabolic, and electrolyte disturbances, wide fluctuations in blood pressure, and arrhythmias. Cyclosporine increases the likelihood of seizures. Diagnostic evaluation should include computerized axial tomography and lumbar puncture to exclude clinically silent neurological lesions or infections. Anticonvulsant therapy should be initiated and, if phenytoin is used, close attention should be paid to its potential interaction with cyclosporine.
Malignancy. Transplant recipients have up to a 6% risk of developing cancer, an age-controlled frequency 100 times greater than that of the general population.'63 Because skin cancer is the most common posttransplant malignancy, dermatological evaluation and protection from solar injury should be practiced routinely. In lymphoproliferative disorders there is a spectrum of abnormal B lymphocyte proliferation. The incidence of such disorders approaches 5% in recipients of thoracic organs'6"; risk is correlated with the degree of total immunosuppression'65 and is believed to result from inadequate T cell control over Epstein-Barr virusdriven B cell proliferation. '64 Reactive lymphoid tissue or highly malignant tumors such as large cell non-Hodgkin's lymphomas may be detected histologically.'66 Both polyclonal and monoclonal proliferation have been identified by cell-surface immunoglobulin phenotype and immunoglobulin rearrangement.'67-173 Lymphoma should be suspected when transplant recipients have fever of undetermined etiology, lymphadenopathy, and elevated Epstein-Barr virus titers. Some of the lymphoproliferative disorders may have a fulminant clinical course with widespread tumor dissemination, organ failure, and sepsis.'64 Because early diagnosis and intervention are believed to improve outcome, all heart transplant recipients should be carefully screened for early signs of posttransplantation lymphoproliferative disorder. Thorough evaluation should include assessment of the gastrointestinal tract and central nervous system in patients in whom lymphoma is suspected. Tissue should be obtained from any suspicious lesion for histology and lymphocyte phenotyping. Bone marrow aspiration and biopsy should be done to exclude bone marrow involvement. For initial treatment of lymphoproliferative disorders, immunosuppression should be reduced where feasible.174 In addition, administration of high-dose intravenous acyclovir may be warranted if the lymphoproliferative disorder is polyclonal. If it is monoclonal, chemotherapy and radiation therapy should be considered. Surgical resection of malignant lesions has been helpful. '68"17",174-'77 In summary, complications following heart transplantation affect several organ systems and vary in type and frequency over time. Because most are due to the effects of immunosuppression, the successful outcome of heart adequate immunosuppression and control of drugrelated adverse effects.
Conclusion
Heart transplantation is a widely accepted treatment for end-stage heart disease. Standard recipient selection criteria exist, but questions requiring further in-depth investigation remain. Controlled trials comparing outcome after transplantation versus medical therapy should be performed. The critical shortage of donors makes it imperative to improve stratification of potential candidates according to preoperative risk.
The high mortality rate of patients awaiting heart transplantation underscores the crucial need to intensify efforts to increase organ donation. Optimal use of donor organs that do become available requires improvement in tissue preservation techniques, identification of ways to optimize donor organ function, and organ allocation based on histocompatibility. Ultimately, heart replacement alternatives such as xenografts (nonhuman transplanted organs), mechanical left ventricular assistance, and dynamic cardiomyoplasty may reduce the number of recipients requiring transplantation of a human heart.
Medical follow-up requires expertise in diagnosis, grading, and treatment of allograft rejection. Appropriate treatment also requires familiarity with individual patients' histories of organ rejection. Overly aggressive immunosuppression of a rejection episode that is likely to resolve spontaneously as well as excessive reduction of the immunosuppressive drug dosage should be avoided. Prescribing a regimen of multiple powerful immunosuppressive drugs while managing their adverse effects is one of the greatest challenges facing transplant physicians. The variable response of individual patients, drug-induced complications, drug interactions, and patient compliance requires constant monitoring and adjustment of the immunosuppressive drug regimen. Cardiologists caring for heart transplant recipients must now be familiar with the pharmacology, drug interactions, and drug toxicity of both agents extensively used in clinical practice (cyclosporine, prednisone, azathioprine, polyclonal and monoclonal anti-T cell agents) and newer treatments (methotrexate, FK-506, rapamycin, mycophenolate mofetil [RS61443], deoxyspergualin, anti-CD4 monoclonal antibodies, total lymphoid irradiation, and photopheresis). Another important aspect of medical follow-up is the detection, differential diagnosis, and treatment of allograft dysfunction. Donor heart physiology is affected by denervation, donorrecipient size and age match, rejection, drug toxicities, and infections. Hemodynamic abnormalities that occur as a result of rejection or a direct drug effect must be differentiated from seemingly physiological changes.
Cardiac allograft vasculopathy is the primary impediment to the long-term survival of heart transplant recipients. Although experimental and clinical evidence suggest that the lesion results from an immune-mediated injury, the pathogenesis of this disorder remains largely unknown. Currently available diagnostic and therapeutic approaches are inadequate. Immunopathogenesis, prevention, early detection, and treatment of allograft vasculopathy should be the major focus of transplantation requires a delicate balance between heart transplantation research.
Heart transplantation has achieved an extraordinary degree of success that in the individual patient depends on a high level of effort at the transplant center and close communication with the physician responsible for long-term treatment.
